Amneal Pharmaceuticals Inc (AMRX)

Currency in USD
21.498
+0.378(+1.79%)
Real-time Data·
AMRX is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
21.07021.650
52 wk Range
11.45022.065
Key Statistics
Prev. Close
21.12
Open
21.07
Day's Range
21.07-21.65
52 wk Range
11.45-22.065
Volume
217K
Average Volume (3m)
3.13M
1-Year Change
85.8081%
Book Value / Share
1.53
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AMRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.286
Upside
+12.97%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Amneal Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.286
(+12.97% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy25.00+16.55%24.00MaintainNov 04, 2026
Piper Sandler
Buy21.00-2.10%-MaintainNov 04, 2026
JPMorgan
Buy24.00+11.89%22.00MaintainOct 22, 2026
UBS
Buy25.00+16.55%25.00MaintainOct 01, 2026
Oppenheimer
Buy27.00+25.87%-New CoverageSep 23, 2026

Amneal Pharmaceuticals Inc SWOT Analysis


Generic Revival
Explore Amneal's robust growth in generics, particularly injectables, driving a 17% increase in Q3 2024 and positioning the company for sustained expansion
Strategic Diversification
Delve into Amneal's multi-pronged growth strategy, encompassing generics, biosimilars, and specialty pharmaceuticals, with a focus on CREXONT's promising launch
Market Dynamics
Analyst targets range from $9 to $12 per share, reflecting optimism about Amneal's potential in the competitive pharmaceutical landscape
Future Challenges
Learn how Amneal plans to navigate the loss of Rytary exclusivity in 2025 and capitalize on biosimilar opportunities amidst regulatory uncertainties
Read full SWOT analysis

Amneal Pharmaceuticals Inc Earnings Call Summary for Q3/2026

  • Amneal reported Q3 2026 adjusted EPS of $0.26, beating estimates by 13%, with revenue of $863M, up 10% YoY, and adjusted EBITDA rising 30% to $207M.
  • Company raised FY 2026 guidance: revenue to $3.15B-$3.25B, adjusted EBITDA to $800M-$815M, and EPS to $1.04-$1.08, reflecting strong operational momentum.
  • Growth driven by biosimilars platform following Kashiv acquisition; lanreotide contributed $7M in Q3, with XOLAIR biosimilar expected H2 2027.
  • Management set 2030 revenue target of $4.3B-$4.5B, primarily from affordable medicines and biosimilars, alongside specialty product expansion.
  • Net leverage rose to 3.0x EBITDA, expected to reach 3.6x by year-end; stock trades at 43x P/E near 52-week high, raising valuation concerns.
Last Updated: 11/03/2026, 10:28 PM
Read Full Transcript

Earnings

Latest Release
Nov 03, 2026
EPS / Forecast
0.26 / 0.23
Revenue / Forecast
862.68M / 812.11M
EPS Revisions
Last 90 days

AMRX Income Statement

Compare AMRX to Peers and Sector

Metrics to compare
AMRX
Peers
Sector
Relationship
P/E Ratio
55.2x12.1x−0.2x
PEG Ratio
0.020.320.00
Price/Book
13.9x1.6x2.6x
Price / LTM Sales
2.3x1.5x2.7x
Upside (Analyst Target)
13.8%4.7%68.5%
Fair Value Upside
Unlock20.6%11.5%Unlock

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson’s disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Employees
8700

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
82.75M23.75%1.76B
Other Institutional Investors
85.52M24.55%1.82B
Public Companies & Retail Investors
180.14M51.70%3.82B
Total
348.41M100.00%7.4B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.62%26,562,093563,913
TPG Capital, L.P.3.54%12,328,767261,740

People Also Watch

36.82
VECO
+0.20%
13.90
OGN
0.00%
43.74
PENG
-0.21%
8.495
BHC
+0.30%
245.13
PAYC
-1.12%

FAQ

What Is the Amneal Pharmaceuticals (AMRX) Stock Price Today?

The Amneal Pharmaceuticals stock price today is 21.498 USD.

What Stock Exchange Does Amneal Pharmaceuticals Trade On?

Amneal Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Amneal Pharmaceuticals?

The stock symbol for Amneal Pharmaceuticals is "AMRX."

What Is the Amneal Pharmaceuticals Market Cap?

As of today, Amneal Pharmaceuticals market cap is 7.500B USD.

What Is Amneal Pharmaceuticals's Earnings Per Share (TTM)?

The Amneal Pharmaceuticals EPS (TTM) is 0.41.

When Is the Next Amneal Pharmaceuticals Earnings Date?

Amneal Pharmaceuticals will release its next earnings report on Feb 26, 2027.

From a Technical Analysis Perspective, Is AMRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Amneal Pharmaceuticals Stock Split?

Amneal Pharmaceuticals has split 0 times.

How Many Employees Does Amneal Pharmaceuticals Have?

Amneal Pharmaceuticals has 8700 employees.

What is the current trading status of Amneal Pharmaceuticals (AMRX)?

As of Nov 18, 2026, Amneal Pharmaceuticals (AMRX) is trading at a price of 21.498 USD, with a previous close of 21.120 USD. The stock has fluctuated within a day range of 21.070 USD to 21.650 USD, while its 52-week range spans from 11.450 USD to 22.065 USD.

What Is Amneal Pharmaceuticals (AMRX) Price Target According to Analysts?

The average 12-month price target for Amneal Pharmaceuticals is 24.286 USD, with a high estimate of 28 USD and a low estimate of 20 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +12.97% Upside potential.

What Is the AMRX Premarket Price?

AMRX's last pre-market stock price is 20.840 USD. The pre-market share volume is 3,610.000, and the stock has decreased by -0.280, or -1.330%.

What Is the AMRX After Hours Price?

AMRX's last after hours stock price is 20.830 USD, the stock has decreased by -0.290, or -1.370%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.